Phathom lowers FY 2026 net revenue guidance to $310–325 mln from $320–345 mln
Company maintains FY 2026 non-GAAP operating expense guidance at $235–245 mln
Phathom expects to achieve operating profitability for remainder and full year 2026, excluding stock-based compensation
Overview
US biopharma firm's Q2 revenue rose 88% yr/yr, beating analyst expectations
Q2 operating expenses fell 33% yr/yr due to lower commercial and personnel costs
Company achieved operating profitability excluding stock-based compensation for the first time
Result drivers and key details
Voquezna prescription growth - Co said revenue increase was driven by higher VOQUEZNA prescription volumes following execution of its commercial strategy
Expense reduction - Operating expenses fell due to lower commercial promotional spend and personnel-related costs
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$74.27 mln
$72.79 mln (9 Analysts)
Q2 Net Loss
$17.58 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
PHAT•
